Table 1 Demographic and clinical baseline data for the three groups
|  | Total | T1 (SHR ≤ 0.838) | T2 (0.838< SHR ≤ 1.140) | T3 (SHR3 > 1.140) |  |
|---|---|---|---|---|---|
|  | N = 1939 | N = 646 | N = 646 | N = 647 | p |
Age (years) | 60(53,69) | 60(53,70) | 60(52,68) | 62 (53,70) | 0.114 |
Male | 1,427 (73.6) | 493 (76.3) | 469 (72.6) | 465 (71.9) | 0.151 |
BMI (kg/m2) | 23.88 (22.04, 26.44) | 23.88 (21.88, 26.11) | 23.86 (21.99, 26.33) | 24.22 (22.05, 26.64) | 0.267 |
SBP (mmHg) | 123 (111, 136) | 124 (112, 135) | 122 (111, 136) | 122 (111, 136) | 0.661 |
DBP (mmHg) | 75 (68, 84) | 76 (68, 85) | 75 (67, 84) | 75 (68, 84) | 0.438 |
Smoking | Â | Â | Â | Â | 0.890 |
 Current | 816 (42.1) | 262 (40.6) | 279 (43.2) | 275 (42.5) |  |
 Former | 282 (14.5) | 99 (15.3) | 91 (14.1) | 92 (14.2) |  |
 Never | 841 (43.4) | 285 (44.1) | 276 (42.7) | 280 (43.3) |  |
Previous stroke | 222 (11.4) | 72 (11.1) | 73 (11.3) | 77 (11.9) | 0.903 |
Family history | 11 (0.6) | 3(0.5) | 3(0.5) | 5 (0.8) | 0.695 |
Previous MI | 794 (40.9) | 283 (43.8) | 254 (39.3) | 257 (39.7) | 0.192 |
Previous PCI | 414 (21.4) | 155 (24.0) | 124 (19.2) | 135 (20.9) | 0.102 |
Previous CABG | 14 (0.7) | 10 (1.5) | 2 (0.3) | 2 (0.3) | 0.010 |
Hypertension grade | Â | Â | Â | Â | 0.588 |
 1 | 116 (6.0) | 38 (5.9) | 39 (6.0) | 39 (6.0) |  |
 2 | 320 (16.5) | 113 (17.5) | 114 (17.6) | 93 (14.4) |  |
 3 | 726 (37.4) | 250 (38.7) | 233 (36.1) | 243 (37.6) |  |
Dyslipidaemia | 855 (44.1) | 266 (41.2) | 288 (44.6) | 301 (46.5) | 0.147 |
DM | 1,138 (58.7) | 378(58.5) | 335(51.9) | 425 (65.7) |  < 0.001 |
Diagnosis on admission |  |  |  |  |  < 0.001 |
 STEMI | 454 (23.4) | 113 (17.5) | 158 (24.5) | 183 (28.3) |  |
 NSTEMI | 454 (23.4) | 154 (23.8) | 156 (24.1) | 144 (22.3) |  |
 UA | 1,031 (53.2) | 379 (58.7) | 332 (51.4) | 320 (49.5) |  |
Transradial approach | 1,838 (94.8) | 623 (96.4) | 615 (95.2) | 600 (92.7) | 0.010 |
LM disease | 103 (5.3) | 41 (6.3) | 38 (5.9) | 24 (3.7) | 0.078 |
LAD disease | 1,262 (65.1) | 401(62.1) | 428 (66.3) | 433 (66.9) | 0.140 |
LCX disease | 604 (31.2) | 203 (31.4) | 194 (30.0) | 207 (32.0) | 0.735 |
RCA disease | 724 (37.3) | 236 (36.5) | 260 (40.2) | 228 (35.2) | 0.155 |
CTO disease | 1,018 (52.5) | 304 (47.1) | 355 (55.0) | 359 (55.5) | 0.003 |
Number of diseased vessels | Â | Â | Â | Â | 0.418 |
 1 | 946 (48.8) | 326 (50.5) | 316 (48.9) | 304 (47.0) |  |
 2 | 619 (31.9) | 198 (30.7) | 197 (30.5) | 224 (34.6) |  |
 3 | 374 (19.3) | 122 (18.9) | 133 (20.6) | 119 (18.4) |  |
Bifurcation lesion | 25 (1.3) | 8(1.2) | 8(1.2) | 9 (1.4) | 0.961 |
Number of stents | 2(1,3) | 2(1,3) | 2(1,3) | 2(1,2) | 0.235 |
Length of stents (mm) | 46 (28, 72) | 48 (29, 74) | 45.5 (28, 73) | 45 (27, 69) | 0.379 |
Diameter of stents (mm) | 3 (2.75, 3.50) | 3 (2.81, 3.50) | 3 (2.75, 3.50) | 3 (2.75, 3.38) | 0.139 |
Thrombolytic therapy | 43 (2.2) | 11 (1.7) | 13 (2.0) | 19 (2.9) | 0.293 |
Drug-coated balloon | 120 (6.2) | 48 (7.4) | 35 (5.4) | 37 (5.7) | 0.270 |
Rotablator | 34 (1.8) | 16 (2.5) | 9 (1.4) | 9 (1.4) | 0.230 |
LVEF (%) | 56 (46.00, 61.00) | 57 (47.25, 61.00) | 55 (45.00, 60.00) | 56 (46.50, 60.00) | 0.033 |
TG (mmol/L) | 1.86 (1.26, 2.92) | 1.66 (1.15, 2.51) | 1.88 (1.27, 2.94) | 2.12 (1.39,3.33) |  < 0.001 |
TC (mmol/L) | 4.79 (3.89, 5.70) | 4.67 (3.82, 5.62) | 4.83 (3.97,5.78) | 4.82 (3.90, 5.71) | 0.096 |
HDL-C (mmol/L) | 1.08 (0.92, 1.25) | 1.07 (0.93, 1.25) | 1.09 (0.94, 1.26) | 1.07 (0.90, 1.25) | 0.129 |
LDL-C (mmol/L) | 2.90 (2.29, 3.57) | 2.84 (2.22, 3.54) | 2.95 (2.33, 3.63) | 2.93 (2.31, 3.56) | 0.125 |
ABG (mmol/L) | 7.75 (5.89, 11.46) | 5.59 (4.82, 6.91) | 7.30 (6.22, 9.68) | 12.04 (9.33, 16.29) |  < 0.001 |
HbA1c (%) | 6.6 (5.8, 8.2) | 6.7 (5.9, 8.2) | 6.2 (5.7, 7.9) | 6.8 (5.8, 8.3) |  < 0.001 |
SHR | 0.97 (0.78, 1.24) | 0.72 (0.63, 0.78) | 0.97 (0.90, 1.05) | 1.40 (1.24, 1.61) |  < 0.001 |
Hb (g/L) | 140.0 (129.0, 152.0) | 139.5 (128.0, 151.0) | 140.0 (129.0, 152.0) | 140.0 (128.5, 152.0) | 0.273 |
Cr (µmol/L) | 77 (65.5, 92.0) | 77 (66.0, 92.0) | 75 (65.0, 90.0) | 78 (66.0, 94.5) | 0.188 |
eGFR (mL/min/1.73 m2) | 89.61 (72.65, 106.14) | 90.20 (73.10, 105.89) | 91.21 (75.44, 106.72) | 87.14 (70.92, 105.43) | 0.074 |
Uric acid (µmol/L) | 354.00 (295.00, 429.00) | 352.00 (300.00, 424.75) | 358.50 (288.00, 433.75) | 350.00 (298.00, 427.00) | 0.664 |
hs-CRP (mg/L) | 3.50 (1.20, 12.38) | 3.50 (1.18,12.08) | 3.45 (1.19, 11.92) | 3.65 (1.24, 14.30) | 0.572 |
Insulin | 476 (24.5) | 130 (20.1) | 136 (21.1) | 210 (32.5) |  < 0.001 |
Oral hypoglycaemic drugs | 897 (46.3) | 307 (47.5) | 265 (41.0) | 325 (50.2) | 0.003 |
Aspirin | 1,906 (98.3) | 635 (98.3) | 638 (98.8) | 633 (97.8) | 0.437 |
P2Y12 inhibitors | 1,920 (99.0) | 645 (99.8) | 635 (98.3) | 640 (98.9) | 0.018 |
Statins | 1,921 (99.1) | 643 (99.5) | 640 (99.1) | 638 (98.6) | 0.221 |
β-blockers | 1,599 (82.5) | 530 (82.0) | 527 (81.6) | 542 (83.8) | 0.551 |
ACEIs/ARBs | 1,529 (78.9) | 524 (81.1) | 518 (80.2) | 487 (75.3) | 0.022 |